Routing in Wireless Multimedia Home Networks

This paper describes an adapted version of the destination sequenced distance vector routing protocol (DSDV) which is suitable to calculate routes in a wireless real-time home network. The home network is based on a IEEE 802.11b ad hoc network and uses a scheduled token to enforce real-time behaviour to support multimedia streams. The multimedia network protocol works for both single-hop and multi-hop networks, however in the latter case special measures have to be taken to forward streams from node to node and to find routes. Existing routing protocols exhibit non-deterministic behaviour which may interfere with the correct streaming of multimedia. The proposed routing protocol does not rely on flooding, instead it piggy-backs the real-time token and behaves in a predictable manner. Simulation of the routing protocol shows that routes in the network are found in finite time

Communicating Personal Gadgets

This paper focuses on communication in personal area networks. A personal area networks (PAN) is characterized as an informal collection, or community, of connected small, lightweight, and resource-lean devices, or gadgets. Two basic concepts are visible in the development of PANs, the distributed and the centralized concept. The paper introduces a real-time communication protocol that is suitable for both concepts. The communication protocol can deal with several types of traffic: real-time or nonreal- time, bursty or isochronous, high or low bitrate. The protocol is undemanding in terms of resources, so even simple devices can participate in the network. The network is simulated and a prototype is realized

To achieve visible impacts horizon Europe must connect to local innovation dynamics

The European Commission aims to use the new Framework Programme for research and innovation – Horizon Europe – to demonstrate to a greater extent than previously that public investments in research and innovation result in real benefits for society. Drawing on research from the Rathenau Instituut, Laurens Hessels, Sue-Yen Tjong Tjin Tai, Julia Jansen and Jasper Deuten, argue that this ambition can only be achieved if the Commission can link European programmes to the interests of localities in ways that also deliver long term transformational changes

The Extraction of Community Structures from Publication Networks to Support Ethnographic Observations of Field Differences in Scientific Communication

The scientific community of researchers in a research specialty is an important unit of analysis for understanding the field specific shaping of scientific communication practices. These scientific communities are, however, a challenging unit of analysis to capture and compare because they overlap, have fuzzy boundaries, and evolve over time. We describe a network analytic approach that reveals the complexities of these communities through examination of their publication networks in combination with insights from ethnographic field studies. We suggest that the structures revealed indicate overlapping sub- communities within a research specialty and we provide evidence that they differ in disciplinary orientation and research practices. By mapping the community structures of scientific fields we aim to increase confidence about the domain of validity of ethnographic observations as well as of collaborative patterns extracted from publication networks thereby enabling the systematic study of field differences. The network analytic methods presented include methods to optimize the delineation of a bibliographic data set in order to adequately represent a research specialty, and methods to extract community structures from this data. We demonstrate the application of these methods in a case study of two research specialties in the physical and chemical sciences.Comment: Accepted for publication in JASIS

A prospective, observational study comparing the PK/PD relationships of generic Meropenem (Mercide®) to the innovator brand in critically ill patients

INTRODUCTION : Clinicians’ skepticism, fueled by evidence of inferiority of some multisource generic antimicrobial products, results in the underutilization of more cost-effective generics, especially in critically ill patients. The aim of this observational study was to demonstrate equivalence between the generic or comparator brand of meropenem (Mercide®) and the leading innovator brand (Meronem®) by means of an ex vivo technique whereby antimicrobial activity is used to estimate plasma concentration of the active moiety. METHODS : Patients from different high care and intensive care units were recruited for observation when prescribed either of the meropenem brands under investigation. Blood samples were collected over 6 hours after a 30 minute infusion of the different brands. Meropenem concentration curves were established against United States Pharmacopeia standard meropenem (Sigma-Aldrich) by using standard laboratory techniques for culture of Klebsiella pneumoniae. Patients’ plasma samples were tested ex vivo, using a disc diffusion assay, to confirm antimicrobial activity and estimate plasma concentrations of the two brands. RESULTS : Both brands of meropenem demonstrated similar curves in donor plasma when concentrations in vials were confirmed. Patient-specific serum concentrations were determined from zones of inhibition against a standard laboratory Klebsiella strain ex vivo, confirming at least similar in vivo concentrations as the concentration curves (90% confidence interval) overlapped; however, the upper limit of the area under the curve for the ratio comparator/innovator exceeded the 1.25-point estimate, i.e., 4% higher for comparator meropenem. CONCLUSION : This observational, in-practice study demonstrates similar ex vivo activity and in vivo plasma concentration time curves for the products under observation. Assay sensitivity is also confirmed. Current registration status of generic small molecules is in place. The products are therefore clinically interchangeable based on registration status as well as bioassay results, demonstrating sufficient overlap for clinical comfort. The slightly higher observed comparator meropenem concentration (4%) is still clinically acceptable due to the large therapeutic index and should ally fears of inferiority.Ranbaxy (S.A) (Pty) Ltdwww.dovepress.comam2016Pharmacolog

A Comprehensive Review on the Surgical Aspect of Lung Transplant Models in Mice and Rats

Lung transplantation improves the outcome and quality of life of patients with end-stage pulmonary disease. However, the procedure is still hampered by the lack of suitable donors, the complexity of the surgery, and the risk of developing chronic lung allograft dysfunction. Over the past decades, translational experiments in animal models have led to a better understanding of physiology and immunopathology following the lung transplant procedure. Small animal models (e.g., rats and mice) are mostly used in experiments regarding immunology and pathobiology and are preferred over large animal models due to the ethical aspects, the cost-benefit balance, and the high throughput possibility. In this comprehensive review, we summarize the reported surgical techniques for lung transplantation in rodent models and the management of perioperative complications. Furthermore, we propose a guide to help identify the appropriate species for a given experiment and discuss recent experimental findings in small animal lung transplant models

Taking One Step Back in Familial Hypercholesterolemia:STAP1 Does Not Alter Plasma LDL (Low-Density Lipoprotein) Cholesterol in Mice and Humans

International audienceSTAP1, encoding for STAP1 (signal transducing adaptor family member 1), has been reported as a candidate gene associated with familial hypercholesterolemia. Unlike established familial hypercholesterolemia genes, expression of STAP1 is absent in liver but mainly observed in immune cells. In this study, we set out to validate STAP1 as a familial hypercholesterolemia gene. Approach and Results: A whole-body Stap1 knockout mouse model (Stap1 -/ - ) was generated and characterized, without showing changes in plasma lipid levels compared with controls. In follow-up studies, bone marrow from Stap1 -/ - mice was transplanted to Ldlr -/ - mice, which did not show significant changes in plasma lipid levels or atherosclerotic lesions. To functionally assess whether STAP1 expression in B cells can affect hepatic function, HepG2 cells were cocultured with peripheral blood mononuclear cells isolated from heterozygotes carriers of STAP1 variants and controls. The peripheral blood mononuclear cells from STAP1 variant carriers and controls showed similar LDLR mRNA and protein levels. Also, LDL (low-density lipoprotein) uptake by HepG2 cells did not differ upon coculturing with peripheral blood mononuclear cells isolated from either STAP1 variant carriers or controls. In addition, plasma lipid profiles of 39 carriers and 71 family controls showed no differences in plasma LDL cholesterol, HDL (high-density lipoprotein) cholesterol, triglycerides, and lipoprotein(a) levels. Similarly, B-cell populations did not differ in a group of 10 STAP1 variant carriers and 10 age- and sex-matched controls. Furthermore, recent data from UK Biobank do not show association between STAP1 rare gene variants and LDL cholesterol

Mammalian cell expression, purification, crystallization and microcrystal data collection of autotaxin/ENPP2, a secreted mammalian glycoprotein

Autotaxin, a four-domain ∼100 kDa mammalian glycoprotein, was expressed in stably transfected mammalian cells, purified from the medium and crystallized. Diffraction data from micrometre-thick crystal plates were collected on various European synchrotron beamlines and are presented and analysed

Feasibility and effectiveness of trifluridine/tipiracil in metastatic colorectal cancer: real-life data from The Netherlands

Background: The RECOURSE trial showed clinical efficacy for trifluridine/tipiracil for refractory metastatic colorectal cancer patients. We assessed the feasibility and effectiveness of trifluridine/tipiracil in daily clinical practice in The Netherlands. Methods: Medical records of patients from 17 centers treated in the trifluridine/tipiracil compassionate use program were reviewed and checked for RECOURSE eligibility criteria. Baseline characteristics, safety, and survival times were compared, and prespecified baseline characteristics were tested in multivariate analyses for prognostic significance on overall survival (OS). Results: A total of 136 patients with a median age of 62 years were analyzed. Forty-three patients (32%) did not meet the RECOURSE eligibility criteria for not having received all prior standard treatments (n = 35, 26%) and/or ECOG performance status (PS) 2 (n = 12, 9%). The most common grade ≥3 toxicities were neutropenia (n = 44, 32%), leukopenia (n = 8, 6%), anemia (n = 7, 5%), and fatigue (n = 7, 5%). Median progression-free survival (PFS) and median OS were 2.1 (95% CI, 1.8–2.3) and 5.4 months (95% CI, 4.0–6.9), respectively. Patients with ECOG PS 2 had a worse median OS (3.2 months) compared to patients with ECOG PS 0–1 (5.9 months). ECOG PS, KRAS-mutation status, white blood cell count, serum lactate dehydrogenase, and alkaline phosphatase were prognostic factors for OS. Conclusions: Our data show that treatment with trifluridine/tipiracil in daily clinical practice is feasible and safe. Differences in patient characteristics between our population and the RECOURSE study population should be taken into account in the interpretation of survival data. Our results argue against the use of trifluridine/tipiracil in patients with ECOG PS 2. Funding: Johannes J.M. Kwakman received an unrestricted research grant from Servier